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Abstract
Geographic heterogeneity has been observed in fracture risk and efficacy of therapeutic intervention in postmenopausal 
osteoporosis. The objectives of these analyses were to assess across geographic and ethnic subgroups the heterogeneity of 
fracture incidence and baseline risk, and consistency of effect of abaloparatide-SC vs placebo on fracture risk reduction in 
the 18-month, phase 3, multinational, ACTIVE randomized controlled trial. Prespecified exploratory analyses of geographic 
subgroups (North America, South America, Europe, Asia) and post hoc analyses of ethnic subgroups (Hispanic or Latino, 
other) of postmenopausal women with osteoporosis enrolled in the abaloparatide-SC and placebo cohorts (n = 1645) were 
performed. Country-specific FRAX models were used to calculate 10-year absolute fracture risks. Relative risk reductions 
for vertebral fractures and hazard ratios for non-vertebral, clinical, and major osteoporotic fractures were calculated. For-
est plots were constructed to assess treatment-by-subgroup interactions for each geographic region and ethnicity. Baseline 
prevalence of vertebral fractures was similar across geographies; baseline prevalence of non-vertebral fractures was more 
variable. Ten-year major osteoporosis fracture and hip fracture risks were variable across and within regions. The effects 
of abaloparatide-SC on reducing the risk of vertebral, non-vertebral, clinical, and major osteoporotic fractures were similar 
across regions, and for Hispanic or Latino vs other ethnicities. A limitation was the limited power to detect interactions 
with few events. In conclusion, despite geographic variability in fracture incidence and risk at baseline, no differences were 
detected in the effects of abaloparatide-SC in reducing vertebral, non-vertebral, clinical, and major osteoporotic fracture risk 
across assessed geographic regions and ethnicities.
Keywords Abaloparatide · Fracture · FRAX · Geography · Osteoporosis
Introduction
Abaloparatide is a 34-amino acid peptide that selectively 
binds to the parathyroid hormone receptor type 1 (PTHR1) 
with high affinity and selectivity for the G protein-dependent 
RG receptor conformation and demonstrates potent anabolic 
activity with less bone resorption and improved tempera-
ture stability compared with teriparatide [1]. In the multina-
tional phase 3 Abaloparatide Comparator Trial in Vertebral 
Endpoints (ACTIVE) trial, postmenopausal women with 
osteoporosis were randomized to receive double-blind daily 
subcutaneous injections of abaloparatide (abaloparatide-
SC) or placebo or open-label teriparatide for 18 months at 
28 sites in 10 countries. Abaloparatide-SC increased bone 
mineral density (BMD) and decreased the risk of vertebral 
and non-vertebral fractures compared with placebo and was 
well-tolerated [2]. Abaloparatide-SC also increased BMD 
earlier at non-vertebral sites and decreased the risk of major 
osteoporotic fractures (hip, forearm, proximal humerus, or 
clinical spine) compared with teriparatide.
Regional and national registration studies have demon-
strated a greater than 10-fold difference in hip fracture rates 
in 63 countries around the world [3]. Additionally, in 40 
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countries with FRAX models to estimate the 10-year abso-
lute risk of fracture, there was a similar heterogeneity in 
the risk of major osteoporotic fractures [3]. A recent report 
suggested that geographic heterogeneity in the risk of non-
vertebral fractures may have contributed to the lack of non-
vertebral risk reduction in a large phase 3 trial with romo-
sozumab, an anabolic agent with a different mechanism of 
action than abaloparatide-SC [4]. Fracture incidence and the 
effectiveness of romosozumab therapy were lower in patients 
from Latin America than in those from the rest of the world. 
Additionally, several analyses have demonstrated variability 
in the interaction of treatment effects when pre-treatment 
fracture probabilities were assessed by FRAX [5]. Given 
the multinational character of the ACTIVE trial, we have 
investigated the fracture incidence and risk at baseline in 
these different geographic regions, and the consistency of 
effect of abaloparatide-SC on fracture reduction.
Methods
Subjects
The multicenter, multinational ACTIVE study enrolled 
postmenopausal women, ages 49–86 years, with osteopo-
rosis as defined by prior radiographic vertebral fracture or 
recent (within 5 years of enrollment) non-vertebral fracture 
with a BMD T-score ≤− 2.5 at the lumbar spine or femoral 
neck if age ≤ 65 years or ≤ − 2.0 if age > 65 years. For those 
aged > 65 years, no prior fracture was required if the lumbar 
spine or femoral neck BMD t score was ≤− 3.0. Other inclu-
sion/exclusion criteria have been previously described [2]. 
The protocol was approved by the respective institutional 
review boards.
Procedures
After informed written consent was obtained; subjects were 
screened and then randomized 1:1:1 to receive either blinded 
daily injections of abaloparatide-SC 80 µg, matching pla-
cebo, or open-label daily subcutaneous injections of teri-
paratide 20 µg for 18 months. These analyses include the 
1645 women in ACTIVE who received abaloparatide-SC or 
placebo. All subjects received supplements of 500–1000 mg/
day elemental calcium and 400–800 IU vitamin D based on 
regional standard of care. The endpoints were assessed as 
previously described [2], including the primary endpoint of 
the incidence of new radiographic vertebral fractures from 
baseline to 18 months in subjects treated with abaloparatide-
SC compared to placebo. Non-vertebral fractures, a second-
ary endpoint, were initially self-reported and then verified 
from source documents and excluded those of the spine, 
sternum, patella, toes, fingers, skull, and face and those 
associated with high trauma, defined as a fall from a height 
equal to or higher than the level of a stool, chair, or first rung 
of a ladder or those associated with severe trauma other than 
a fall. Prespecified exploratory endpoints included clinical 
fractures (all fractures that would cause a patient to seek 
medical care, regardless of the level of trauma, including 
clinical spine fractures) and major osteoporotic fractures 
(upper arm, forearm, hip, or clinical spine fractures). Study 
oversight was performed and safety was assessed as pre-
viously described [2], and all assessors of fracture were 
blinded to treatment assignment.
Statistical Analyses
To evaluate whether the effects of abaloparatide-SC vs pla-
cebo on vertebral, non-vertebral, clinical, and major osteo-
porotic fractures were consistent in different geographical 
regions, these endpoints were analyzed by subgroups pre-
specified by the regions of North America, South America, 
Europe, and Asia, as previously described for other sub-
groups [6]. Relative risk ratios for new vertebral fractures 
and hazard ratios for all other fractures were calculated as 
previously described [2]. Forest plots were constructed to 
assess qualitative treatment-by-subgroup interactions, and 
this was further assessed qualitatively and quantitatively by 
the Breslow–Day test for vertebral fractures and the Cox 
proportional hazards model for non-vertebral, clinical, and 
major osteoporotic fractures. Analyses for interactions were 
not controlled for covariates other than subgroup, treatment, 
and treatment-by-subgroup interaction in the Cox model. 
The consistency of the effect of abaloparatide-SC vs placebo 
on vertebral, non-vertebral, clinical, and major osteoporo-
tic fractures was tested in post hoc analyses in Hispanic or 
Latino and in non-Hispanic or Latino populations from all 
geographies. P values were not adjusted for multiple com-
parisons and were considered significant if p < 0.05.
To evaluate absolute fracture risk at baseline, the pre-
specified exploratory FRAX analyses were performed as 
previously described [5]. FRAX models were used for each 
country including the United States in North America; 
Argentina and Brazil in South America; the Czech Repub-
lic, Denmark, Estonia, Lithuania, Poland, and Romania in 
Europe; and Hong Kong in Asia. Ethnic-specific models 
were used in the United States. The baseline clinical risk 
factors of age, BMI, prior fragility fracture, current tobacco 
smoking, ever long-term use of oral glucocorticoids, rheu-
matoid arthritis, other causes of secondary osteoporosis, 
and daily consumption of 3 or more units of alcohol were 
entered into the country-specific FRAX models to calculate 
the 10-year probability of major osteoporotic fracture and 
hip fracture with and without the inclusion of femoral neck 
BMD using the FRAX tool (http://www.shef.ac.uk/FRAX/). 
A prior fracture was considered present in the FRAX model 
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if there was either a history of prior non-vertebral fracture 
or a vertebral fracture of semiquantitative grade 2 or 3 docu-
mented by radiography at baseline. Current tobacco smok-
ing was assumed if the subjects responded positively to the 
question of smoking in the last 5 years. Ever long-term use 
of oral glucocorticoids was set to no for all subjects, as this 
was an exclusion criterion for the study. As parental history 
of hip fracture was not captured, this risk factor was set to 
no. A history of rheumatoid arthritis was captured from the 
medical history. The diagnosis of secondary osteoporosis 
was based on the medical history and comprised type 1 dia-
betes mellitus, malnutrition, liver disorders, and premature 
menopause. Daily consumption of alcohol was reported if 
the subject consumed 21 or more units per week.
Results
The baseline characteristics for each region are presented 
in Table 1. The women in South America and Asia were 
slightly older than those in North America and Europe. As 
expected, the BMI was lower in women from Asia than 
those from other regions. Among 398 Hispanic or Latino 
women in the study population, 338 (85%) were white. 
The baseline prevalence of vertebral fractures was similar 
across geographies, ranging from 18.0% in South America 
to 25.3% in Europe. However, the baseline prior history of 
non-vertebral fractures was more variable, ranging from 
32.2% in Asia to 80.0% in North America. At baseline in 
the overall population, the 10-year risk of major osteoporotic 
fracture (± SD) was 13.2 ± 7.9% and that for hip fracture 
was 4.8 ± 4.7% in the FRAX model including BMD and 
13.3 ± 8.1% and 5.1 ± 4.8%, respectively, in the model with-
out BMD. Using the FRAX model with BMD, the 10-year 
major fracture risks ranged from 8.8% in South America to 
17.7% in Asia and risks for hip fracture ranged from 3.7% 
in South America to 8.3% in Asia, but the variability was 
high (Table 1). There was also variability within regions. For 
example, within Europe, the 10-year hip fracture risk ranged 
from 1.6% in Romania to 7.0% in Denmark and in South 
America the risk was 3.6% in Brazil and 5.2% in Argentina. 
The subgroups were well matched across the placebo and 
abaloparatide-SC groups, although some of the subgroups 
were small (Table 1).
In the overall population, abaloparatide-SC reduced the 
risk of vertebral fractures from 4.2% in the placebo group 
to 0.6% in the treatment group [relative risk (RR) 0.14, 95% 
confidence interval (CI) 0.05–0.39, p < 0.001] [2]. As shown 
in the Forest plot (Fig. 1), the effect of abaloparatide-SC in 
reducing the risk of vertebral fractures was similar in South 
America, Europe, and Asia, although the numbers of events 
were small in South America and Asia and there were no 
new vertebral fractures in subjects from North America. 
There was no significant treatment-by-subgroup interaction 
(p = 0.57).
Overall, abaloparatide-SC reduced the risk of non-verte-
bral fractures from 4.7% in the placebo group to 2.7% in the 
treatment group [hazard ratio (HR) 0.57, 95% CI 0.32–1.0, 
p = 0.049] [2]. The Forest plot (Fig. 1) shows similar effects 
in South America and Europe; there were few events in Asia 
and none in North America. Again, there was no significant 
treatment-by-subgroup interaction (p = 0.89).
Similar results were found for the prespecified explora-
tory endpoints of clinical fractures and major osteoporotic 
fractures. Overall, abaloparatide-SC reduced the risk of clin-
ical fractures from 8.3% in the placebo group to 4.0% in the 
treatment group (HR 0.57, 95% CI 0.35–0.91, p = 0.02) and 
reduced the risk of major osteoporotic fractures from 6.2% in 
the placebo group to 1.5% in the treatment group (HR 0.30, 
95% CI 0.15–0.61, p < 0.001) (2). The Forest plot (Fig. 1) 
again demonstrates similar effects across regions with no 
fractures in North America and no significant treatment-
by-subgroup interactions (p = 0.83 and p = 0.76 for clinical 
fractures and major osteoporotic fractures, respectively).
The effect of abaloparatide-SC in reducing the risk of ver-
tebral fractures was similar in the Hispanic or Latino popula-
tion (RR 0.35, 95% CI 0.04–3.36) vs other ethnicities (RR 
0.11, 95% CI 0.03–0.37), interaction p = 0.35 (Fig. 2). Like-
wise, the effect of abaloparatide-SC on reducing the risk of 
non-vertebral fractures was similar in the Hispanic or Latino 
population (HR 0.75, 95% CI 0.24–2.36) vs other ethnicities 
(HR 0.52, 95% CI 0.27–1.01), interaction p = 0.57. There 
were also no significant treatment-by-subgroup interactions 
for the prespecified exploratory endpoints of clinical frac-
tures and major osteoporotic fractures (p = 0.33 and 0.65, 
respectively).
Discussion
No differences were detected in the effects of abaloparatide-
SC in reducing the risks of fracture across the four geo-
graphical regions assessed. These comparable effects were 
achieved for vertebral, non-vertebral, clinical, and major 
osteoporotic fractures despite the variability in fracture inci-
dence and in the FRAX-derived estimates of fracture risk 
observed across regions and even across countries within 
specific regions. Although the same inclusion criteria were 
used for enrollment in all geographic regions, fracture inci-
dence was higher in European compared to South Ameri-
can patients, consistent with the higher FRAX estimates 
of fracture probability in the Europe subgroup than in the 
South American subgroup. This variability in fracture risk 
has been documented in the past and may be related more 
to environmental rather than to genetic factors [3]. These 
results are consistent with a post hoc analysis demonstrating 
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that the efficacy of abaloparatide-SC to decrease the risk of 
major osteoporotic fracture or any clinical fracture in post-
menopausal women with low BMD and/or prior fracture 
appears independent of baseline fracture probability [5].
Similar results have been found with denosumab for 
effects on vertebral fracture across the regions of West-
ern Europe/Australia/New Zealand, Eastern Europe, Latin 
America, and North America [7]. Likewise, the effects of 
zoledronic acid on vertebral, hip, and non-vertebral frac-
tures were independent of the regions of the Americas, 
Asia, and Europe [8]. However, in a post hoc analysis, the 
effect of romosozumab on non-vertebral fracture risk was 
different in Latin America compared to other regions [4]. 
Analyses of geographic variations in the results of rand-
omized, controlled trials suggest that although most geo-
graphic variations are likely due to chance, some may rep-
resent true benefit or harm of the intervention and that the 
overall average result of a trial is usually a more reliable 
estimate of the treatment effect in the subgroups than the 
observed effects in individual subgroups [9]. Consistency 
of results with those seen in other trials of the same or 
similar interventions has been suggested as one criterion 
to guide interpretation of a trial that shows variations in 
treatment effects across geographies [9].
The majority of subjects in both North America and 
South America were of Hispanic or Latino ethnicity. Aba-
loparatide-SC also reduced the risk of fracture to a similar 
degree in women of Hispanic or Latino ethnicity compared 
to those of other ethnicities. In the United States, rates 
of fracture are lower in Hispanic women than in white 
women, although there is some variability by fracture site 
[10]. Additionally, the Hispanic community is diverse, and 
there are regional differences in hip fracture incidences for 
Hispanics in the United States [11].
The strengths of this study include the diverse popu-
lations studied and the prespecified analyses of regional 
subgroups. The major limitation is that the study was not 
powered to detect interactions in small groups with few 
events and wide confidence intervals. Therefore, these 
analyses cannot exclude the possibility of a treatment 
effect in some subgroups, especially in the small Asian 
subgroups. Another important limitation is possible selec-
tion bias in that clinical trial subjects may not be truly 
representative of the general population. Additionally, 
Fig. 1  Relative risk ratios for 
new vertebral fractures and 
hazard ratios for non-vertebral, 
clinical, and major osteoporo-
tic fractures in placebo vs 
abaloparatide-SC groups by 
geographical region. RR relative 
risk, HR hazard ratio; CI confi-
dence interval
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statistical significance was assessed without adjustment 
for multiple comparisons.
In conclusion, in postmenopausal women with osteoporo-
sis, no differences were detected in the effects of abalopara-
tide-SC in reducing vertebral, non-vertebral, clinical, and 
major osteoporotic fracture risk across different geographic 
regions and in different ethnicities, despite the geographical 
variability in baseline fracture incidence and risk.
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